This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
NextGen Healthcare (NXGN) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
NextGen Healthcare's (NXGN) fiscal first-quarter earnings reflect strong segmental performance.
Cerner (CERN) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Cerner's (CERN) second-quarter results benefit from gains across six of its business units.
LabCorp (LH) Q2 Earnings Surpass Estimates, 2021 View Raised
by Zacks Equity Research
LabCorp (LH) Diagnostics revenues in the second quarter increase significantly on organic Base Business volume improvements despite decelerating demand for COVID-19 testing.
LabCorp (LH) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
LabCorp (LH) delivered earnings and revenue surprises of 8.69% and 7.08%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
LabCorp (LH) to Report Q2 Earnings: What's in the Cards? (revised)
by Zacks Equity Research
LabCorp's (LH) second-quarter base-business performance is expected to have registered a faster recovery rate compared to the first quarter.
What's in Store for Henry Schein (HSIC) in Q2 Earnings?
by Zacks Equity Research
Henry Schein's (HSIC) PPE sales from medical business are likely to have maintained momentum in Q2. Also, global recovery trends of its dental business are expected to reflect on Q2 results.
STERIS (STE) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Acquisitions of Cantel Medical and Key Surgical are expected to have contributed significantly to STERIS' (STE) first-quarter revenues.
What's in Store for IDEXX Laboratories (IDXX) in Q2 Earnings?
by Zacks Equity Research
IDEXX's (IDXX) fiscal second-quarter top line is expected to have benefited from strength in CAG and LPD businesses.
LabCorp (LH) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
LabCorp (LH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Breast Health Sales to Aid Hologic's (HOLX) Q3 Earnings
by Zacks Equity Research
The acquisition of Biotheranostics and relaunch of Brevera are expected to have contributed to Hologic's (HOLX) Breast Health arm performance in the third quarter.
Should You Invest in the SPDR S&P Health Care Services ETF (XHS)?
by Zacks Equity Research
Sector ETF report for XHS
Can LabCorp (LH) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
LabCorp (LH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
LabCorp (LH) to Report Q2 Earnings: What's in the Cards? (revised)
by Zacks Equity Research
LabCorp's (LH) second-quarter base-business performance is expected to have registered a faster recovery rate compared to the first quarter.
What's in Store for Edwards Lifesciences (EW) Q2 Earnings?
by Zacks Equity Research
Continued adoption of TruWave disposable pressure monitoring devices and progress in transfemoral EVOQUE and SAPIEN M3 platforms are likely to have driven Edwards Lifesciences' (EW) Q2 revenues.
Bio-Rad (BIO) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Improvement in demand at non-COVID business and continued strength in Bio-Rad's (BIO) Life Science segment are likely to have contributed to Q2 results.
LabCorp (LH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
LabCorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Align Technology (ALGN) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Continued adoption of Invisalign Clear Aligners and iTero scanners are expected to have contributed to the Align Technology's (ALGN) second-quarter 2021 results.
Hologic (HOLX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Hologic's (HOLX) recent acquisitions and product launches are expected to contribute significantly to its third-quarter performance.
Boston Scientific (BSX) Watchman FLX Sales to Aid Q2 Earnings
by Zacks Equity Research
Strong procedure recovery and market share gains across many of the businesses and regions are expected to have boosted Boston Scientific's (BSX) Q2 sales.
Quest Diagnostics (DGX) Expands Testing Access With CLX Pact
by Zacks Equity Research
Quest Diagnostics' (DGX) COVID-19 testing will be available through TrustAssure platform for international travelers and live event attendants.
Cardinal Health (CAH) Introduces 2 New Digital Solutions
by Zacks Equity Research
Cardinal Health (CAH) launches NavixRx Compliance Packaging and E-Commerce Storefront to allow independent pharmacists to expand services and support medication adherence.
Integra (IART) Releases Favorable PriMatrix Clinical Outcome
by Zacks Equity Research
Integra's (IART) PriMatrix study data validates that one application of PriMatrix is needed to address hard-to-heal diabetic foot ulcers.
Base Test Rebound to Drive Quest Diagnostics (DGX) Q2 Earnings
by Zacks Equity Research
Quest Diagnostics' (DGX) second-quarter performance within its non-COVID base business might have registered significant sales rebound.
Zacks Earnings ESP: A Better Way to Find Earnings Surprises for Medical
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Are Investors Undervaluing LabCorp (LH) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.